Tests baricitinib to delay type 1 diabetes in people at high risk
Tests baricitinib against placebo in people at high risk of type 1 diabetes.
Plain-language title generated from the registry record
Registry title: A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Key facts
- Where
- Ancona, Bologna, Cagliari, Florence, Milan, Naples, Novara, Padova, and Verona, ItalySee the 9 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 35 years old?
Source: NCT07222137, who can take part
Where in Italy
- Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I G M Lancisi G SalesiAncona, ItalyTaking people
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoBologna, ItalyTaking people
- Azienda Socio Sanitaria Locale N. 8 Di CagliariCagliari, ItalyTaking people
- Azienda Ospedaliera Universitaria Meyer IRCCSFlorence, ItalyTaking people
- Ospedale San Raffaele S.r.l.Milan, ItalyTaking people
- Azienda Ospedaliera Universitaria Federico II Di NapoliNaples, ItalyTaking people
- Azienda Ospedaliero Universitaria Maggiore della CaritàNovara, ItalyTaking people
- Azienda Ospedaliera di PadovaPadova, ItalyTaking people
- Azienda Ospedaliera Universitaria Integrata VeronaVerona, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07222137EU 2025-521797-34-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.Read full original descriptionShow less
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Inclusion: Have a history of at least one documented occasion of at least two diabetes-related autoantibodies, AND one occasion of at least two diabetes-related autoantibodies obtained at screening or prescreening; Have Stage 1b or Stage 2 type 1 diabetes; Have a body weight of ≥8 kilograms (kg) (18 pounds) at screening.
Exclusion: Have any other type of diabetes; Have had a heart attack, heart disease, stroke, or heart failure; Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy; Have a current or recent clinically serious infection; Have uncontrolled high blood pressure.